Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-626P is a human pseudogene derived from the U6 small nuclear RNA (snRNA) family, designated as "RNA, U6 small nuclear 626, pseudogene." Pseudogenes like RNU6-626P originate from functional genes but accumulate mutations that prevent their expression as functional RNAs or proteins. U6 snRNA is a central component of the spliceosome, essential for mRNA splicing in eukaryotes; however, this pseudogene is not known to be transcribed into a functional RNA and has no established biological function, disease association, interaction with drugs, or role as a therapeutic target[4][5]. The presence of multiple U6 pseudogenes in the genome is believed to reflect the evolutionary importance of the canonical U6 snRNA, but pseudogenes themselves, including RNU6-626P, are not considered functional or directly involved in cellular processes[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 626, pseudogene (RNU6-626P).